Adaptive Biotechnologies targets 30%+ clonoSEQ test volume growth in 2026 while expanding margins and data partnerships
Adaptive Biotechnologies Corporation Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $15.23
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS